View Older Stories

Feb 24, 2026 08:33AM KeyBanc Reiterates Sector Weight Rating on Hims and Hers (HIMS)

Feb 24, 2026 07:51AM BTIG Downgrades Hims and Hers (HIMS) to Neutral

Feb 24, 2026 06:27AM Hims and Hers (HIMS) PT Lowered to $17.50 at Leerink Partners

Feb 24, 2026 05:27AM Hims and Hers (HIMS) PT Lowered to $24 at Evercore ISI

Feb 24, 2026 05:11AM Hims and Hers (HIMS) PT Lowered to $12.50 at BofA Securities

Feb 23, 2026 04:42PM After-hours movers: Hims & Hers Health, Keysight, Bed Bath & Beyond, Myriad Genetics, and more

Feb 23, 2026 04:07PM Hims & Hers Health, Inc. (HIMS) Tops Q4 EPS by 3c, Offers Guidance

Feb 23, 2026 12:00PM Hims & Hers is due to report after the bell. Here's what to watch out for.

Feb 23, 2026 04:00AM Hims & Hers Health Inc. set to report Q4 earnings with guidance cut fears mounting after compounded semaglutide fallout

Feb 22, 2026 03:00PM Hims & Hers Health (HIMS) stock: Should you buy the dip after massive selloff?

Feb 10, 2026 06:01AM Hims and Hers (HIMS) PT Lowered to $30 at Canaccord Genuity

Feb 9, 2026 12:13PM Hims and Hers (HIMS) PT Lowered to $13 at BofA Securities

Feb 9, 2026 08:26AM Hims and Hers (HIMS) PT Lowered to $20 at Leerink Partners

Feb 9, 2026 07:14AM Needham Reiterates Hold Rating on Hims and Hers (HIMS)

Feb 9, 2026 07:00AM Novo Nordisk sues Hims & Hers over compounded semaglutide products

Feb 9, 2026 06:53AM Novo Nordisk jumps, Hims shares plummet after pulling $49 weight-loss pill

Feb 9, 2026 06:41AM BTIG Reiterates Buy Rating on Hims and Hers (HIMS)

Feb 9, 2026 05:56AM Hims & Hers Health, Inc. (HIMS) call put ratio 1.2 calls to 1 put into stopping offering access to semaglutide pill

Feb 9, 2026 05:52AM Morgan Stanley Reiterates Equalweight Rating on Hims and Hers (HIMS)

Feb 9, 2026 05:37AM Hims and Hers (HIMS) PT Lowered to $21 at BofA Securities

Feb 9, 2026 04:45AM Hims & Hers Health (HIMS) said to stop offering weight loss pill

Feb 6, 2026 04:51PM FDA moves to restrict copycat GLP-1 weight loss drugs

Feb 6, 2026 07:58AM Hims & Hers stock falls after FDA warns against illegal copycat drugs

Feb 6, 2026 06:04AM TD Cowen Reiterates Hold Rating on Hims and Hers (HIMS)

Feb 5, 2026 12:35PM Truist: 'Defending Lilly: LLY strong position helps guard their share in a crowded GLP-1 landscape'

Feb 5, 2026 10:46AM Novo Nordisk threatens legal action over Hims & Hers semaglutide pill

Feb 5, 2026 10:25AM Leerink: 'there is no reason why HIMS shouldn't evaluate these launches for every subsequent weight loss product'

Feb 5, 2026 10:24AM Wolfe Research on Eli Lilly (LLY): 'we question the legality of HIMS' ability to market an oral semaglutide'

Feb 5, 2026 10:10AM Wells Fargo on Eli Lilly (LLY): 'Compounders Strike Again, but We See Little Risk to Near-Term Growth'

Feb 5, 2026 09:58AM BMO Capital: 'Novo Mgmt Meetings Highlight Deep Strategic Challenges'

Feb 5, 2026 09:08AM Hims stock surges as Wegovy pill copy offered at $49, Novo shares fall

Feb 5, 2026 09:01AM Hims & Hers adds compounded semaglutide pills starting at $49 monthly

Feb 5, 2026 08:52AM Hims & Hers Health (HIMS) launches a copy of Wegovy pill at $49/month

Feb 4, 2026 09:07AM HIMS launches multi-cancer screening blood test through GRAIL partnership

Jan 20, 2026 04:53AM Morgan Stanley Reiterates Equalweight Rating on Hims and Hers (HIMS)

Jan 12, 2026 06:01AM Evercore ISI Starts Hims and Hers (HIMS) at In Line

Jan 8, 2026 05:14AM Hims and Hers (HIMS) PT Lowered to $29 at BofA Securities, 'Sales and EBITDA margin expectations are too high'

Dec 19, 2025 05:12AM BofA on Hims and Hers (HIMS): 'November data: Sales steady, orders still weaker, and December will determine 4Q'

Dec 10, 2025 04:07AM Hims & Hers launches weight loss program in UK with Hers platform

Dec 8, 2025 07:30AM Truist Securities Reiterates Hold Rating on Hims and Hers (HIMS), PT $37, 'Q4 revenues tracking below guidance and consensus'

Dec 4, 2025 09:19AM Hims and Hers (HIMS) PT Lowered to $41 at Leerink Partners

Dec 4, 2025 07:00AM Hims & Hers expands into Canada through Livewell acquisition

Dec 4, 2025 07:00AM HIMS enters Canada market through Livewell acquisition

Nov 17, 2025 07:46AM Novo Nordisk cuts cash prices for Wegovy and Ozempic to $199 monthly

Nov 17, 2025 06:01AM Hims & Hers appoints Deb Autor as first chief policy officer

Nov 13, 2025 12:00PM HIMS launches Labs testing service with two pricing tiers

Nov 13, 2025 11:47AM Truist: 'Klarna Partnership Aligns with HIMS' Focus on Improving Affordability'

Nov 13, 2025 11:45AM Hims & Hers Health, Inc. (HIMS) To Offer Lab Testing To Boost Growth - DJ

Nov 12, 2025 06:41AM Morgan Stanley on Hims and Hers (HIMS): 'October Data Continues to Trend in the Wrong Direction'

Nov 6, 2025 01:17PM Needham: 'GLP-1 Price Cuts Limit HIMS Competitive Advantage'

View Older Stories